% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • jrus2010 jrus2010 Oct 28, 2010 3:30 AM Flag

    Sanofi taking larger than expected hit on Lovenox

    Sanofi just released its Q3 earning report. Key takeaways:

    1. For Q3, Lovenox US sales down 47.2%, and Lovenox global sales down 26.1%
    2. Lovenox Euro589M actual sales for Q3 well below concensus estimates (Euro656M) and estimates in last 2 days by Goldman Sachs (Euro606M) and Cowen (Euro631M)
    3. Sanofi overall US sales down 6.2% overall, and Sanofi overall global sales down 1.7% overall
    4. Business net income down 2.2% on a CER basis

    Sanofi's Lovenox franchise is now officially in deep trouble. Lovenox sales came in below even the lowest analyst expectation (Goldman Sachs). This wasn't even a full quarter of sales.

    Bodes well for Momenta

12.20-0.51(-4.01%)Aug 26 4:00 PMEDT